Equities research analysts expect Alliqua BioMedical, Inc. (NASDAQ:ALQA) to announce earnings per share (EPS) of ($0.70) for the current quarter, Zacks reports. Two analysts have made estimates for Alliqua BioMedical’s earnings. Alliqua BioMedical posted earnings per share of ($6.10) during the same quarter last year, which suggests a positive year over year growth rate of 88.5%. The business is scheduled to announce its next earnings results on Tuesday, March 6th.
On average, analysts expect that Alliqua BioMedical will report full-year earnings of ($3.90) per share for the current fiscal year. For the next year, analysts anticipate that the business will post earnings of ($2.10) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Alliqua BioMedical.
ALQA has been the subject of several research reports. ValuEngine upgraded shares of Alliqua BioMedical from a “sell” rating to a “hold” rating in a research note on Friday, October 6th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Alliqua BioMedical in a research note on Monday, September 18th. Finally, Zacks Investment Research upgraded shares of Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a research note on Tuesday, September 12th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Alliqua BioMedical has a consensus rating of “Buy” and a consensus target price of $11.25.
An institutional investor recently raised its position in Alliqua BioMedical stock. KCG Holdings Inc. grew its stake in shares of Alliqua BioMedical, Inc. (NASDAQ:ALQA) by 777.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 525,077 shares of the company’s stock after acquiring an additional 465,256 shares during the quarter. KCG Holdings Inc.’s holdings in Alliqua BioMedical were worth $265,000 as of its most recent SEC filing.
TRADEMARK VIOLATION WARNING: “Alliqua BioMedical, Inc. (ALQA) Expected to Announce Earnings of -$0.70 Per Share” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://weekherald.com/2017/11/15/alliqua-biomedical-inc-alqa-expected-to-announce-earnings-of-0-70-per-share.html.
Alliqua BioMedical (NASDAQ:ALQA) opened at $2.04 on Wednesday. Alliqua BioMedical has a 12 month low of $1.99 and a 12 month high of $8.50.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.